Condition: Advanced Solid Tumor · Advanced Breast Cancer · Metastatic Breast Cancer · Sponsor: BeOne Medicines
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
This description comes directly from the study's public registry record.
Study Director · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Sarah Cannon Research Institute (Scri) At Health One | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists and Research Institute | Lake Mary, Florida, United States | Completed |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Completed |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| Scri Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Next Dallas | Irving, Texas, United States | Recruiting |
| Next Oncology | San Antonio, Texas, United States | Recruiting |
| Blacktown Cancer and Haematology Centre | Blacktown, New South Wales, Australia | Recruiting |
| Southern Highlands Private Hospital | Bowral, New South Wales, Australia | Recruiting |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06120283